Guggenheim Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)

July 2, 2025 6:12 AM EDT Send to a Friend
Guggenheim analyst Seamus Fernandez reiterated a Buy rating and $116.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login